India’s Precision Medicine: A Vision Hindered by Biobank Regulations
Precision medicine, a transformative approach to healthcare, is redefining the landscape of disease diagnosis and treatment. From groundbreaking personalised healthcare solutions to innovations like mRNA vaccines and gene-editing technologies, the field promises a new era in medical science. Yet, as India stands on the cusp of this revolution, a significant hurdle looms: the lack of robust biobank regulations.
Biobanks, essential repositories of biological samples, are critical to the success of precision medicine. These collections of blood, DNA, and tissue samples, coupled with genetic data, form the backbone of research aimed at developing targeted therapies for diseases like cancer and diabetes. However, as highlighted in a recent analysis by The Hindu, India’s inconsistent biobank regulations threaten public trust and impede progress.
The Promise of Precision Medicine
In recent years, precision medicine has witnessed remarkable achievements. Through gene therapy, researchers have restored vision in individuals with genetic mutations, while in the U.K., scientists have reversed diabetes using reengineered stem cells. The rapid development of COVID-19 vaccines using the mRNA platform, which earned a Nobel Prize, further underscores the potential of precision medicine.
India’s Growing Market
The Indian precision medicine market is burgeoning, with projections estimating a value exceeding $5 billion by 2030. Initiatives like the BioE3 policy and the approval of NexCAR19, a domestically developed CAR-T cell therapy, mark significant strides. However, the true potential of these advancements lies in aligning biobank regulations with international standards.
The Biobank Conundrum
While countries like the U.K., U.S., and Japan have comprehensive biobank regulations ensuring data protection and privacy, India’s framework remains fragmented. The absence of a single authority to regulate biobanks and the lack of penalties for misconduct create risks of ethical violations and undermine public confidence. As the ICMR guidelines illustrate, participants often consent to provide samples without clarity on data usage, raising concerns about privacy and potential discrimination.
A Path Forward
To harness the full potential of precision medicine, India must establish stringent biobank regulations. Aligning with global standards will not only bolster public trust but also position India as a leader in next-generation therapeutics. As part of international groups like the Quad and BRICS, India has the opportunity to expand its pharmaceutical leadership and enhance its soft diplomatic efforts.
Manjeera Gowravaram, a PhD in RNA biochemistry, provides insightful analysis on the intersection of science and policy.
More Articles
Getting licensed or staying ahead in your career can be a journey—but it doesn’t have to be overwhelming. Grab your favorite coffee or tea, take a moment to relax, and browse through our articles. Whether you’re just starting out or renewing your expertise, we’ve got tips, insights, and advice to keep you moving forward. Here’s to your success—one sip and one step at a time!
The commercial real estate industry is finally confronting years of delayed financial reality as banks begin calling in billions in troubled loans, pushing office loan delinquencies to record highs. With more than 12 percent of office loans now delinquent and nearly a trillion dollars in commercial and multifamily debt maturing this year, lenders are tightening standards and forcing borrowers to present real data, stronger strategies, and actionable plans. Regional banks face the most risk, while real estate professionals who master data literacy and investment analysis will be best positioned to thrive in this new era.
CFP professionals are in higher demand than ever, and new data from SmartAsset and the CFP Board shows that some states are becoming hotspots for this booming field. California leads the nation, now home to nearly one in every ten Certified Financial Planners. As Americans seek deeper financial guidance, states with strong economies and growing populations are seeing the fastest rise in licensed advisors—signaling major opportunity for both new and seasoned professionals.
After years of market disruption, commercial real estate is finally showing strong signs of a comeback, with major investment firms projecting 2026 as the year the sector fully stabilizes. New reports from Hines, CBRE, and Colliers point to rising leasing activity, renewed buyer appetite, and a rebound toward pre‑pandemic investment levels. Manhattan is leading the recovery, premium office spaces are dominating demand, and suburban markets are gaining traction—setting the stage for significant opportunities for real estate professionals, investors, and brokers preparing for the next market cycle.
The 2026 labor market is entering a “low‑hire, low‑fire” freeze—job openings remain above pre‑pandemic levels, yet companies are delaying hiring decisions as they navigate economic uncertainty, tariffs, and shifting immigration policies. Despite the slowdown, major pockets of growth remain, especially in healthcare, construction, civil engineering, and Sunbelt regions. AI is reshaping some industries but replacing very few jobs, with less than 1% of skills at high risk of automation. For professionals willing to adapt, upskill, or shift industries, 2026 offers strategic opportunities—particularly in licensed fields like real estate, mortgage, insurance, and finance, where education and credentials can unlock stability and upward mobility.
Mortgage rates slipped to 6.09% this week, marking their lowest point in three years and surprising analysts after strong job numbers. The drop improves affordability for many families and signals a pivotal moment for buyers, investors, and real estate professionals as market conditions cool and stabilization continues into 2026.
Artificial intelligence is now the driving force behind the fastest‑growing proptech companies, with AI-native startups claiming the majority of the $16.7 billion invested in real estate technology last year. From tenant communication automation to self‑navigating construction vehicles and AI-powered investor management systems, four new unicorns—EliseAI, Bedrock Robotics, Juniper Square, and Vantaca—are leading a sweeping shift across commercial real estate. Their rise signals a new era where professionals must embrace automation, data skills, and continuous education to stay competitive in an industry evolving at record speed.
Biobanks, essential repositories of biological samples, are critical to the success of precision medicine. These collections of blood, DNA, and tissue samples, coupled with genetic data, form the backbone of research aimed at developing targeted therapies for diseases like cancer and diabetes. However, as highlighted in a recent 
While countries like the U.K., U.S., and Japan have comprehensive biobank regulations ensuring data protection and privacy, India’s framework remains fragmented. The absence of a single authority to regulate biobanks and the lack of penalties for misconduct create risks of ethical violations and undermine public confidence. As the 
